Cargando…

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)

Background: Recent major randomized trials revealed the superiority of non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) from 6 months to 2 years after percutaneous coronary intervention (PCI). However, whether NOAC monotherapy superiority over warfarin continues...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozaki, Yukio, Kawai, Hideki, Muramatsu, Takashi, Harada, Masahide, Takahashi, Hiroshi, Ishii, Hideki, Maekawa, Yuichiro, Ismail, Tevfik F., Amano, Tetsuya, Izawa, Hideo, Murohara, Toyoaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2022
Materias:	Protocol Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726694/ https://www.ncbi.nlm.nih.gov/pubmed/36530841 http://dx.doi.org/10.1253/circrep.CR-22-0096

Ejemplares similares

Nucleosomes get peeled and rewrapped
por: LeBrasseur, Nicole
Publicado: (2003)

Pharmacological Prevention of Peri-, and Post-Procedural Myocardial Injury in Percutaneous Coronary Intervention
por: Ishii, Hideki, et al.
Publicado: (2008)

A multicenter prospective cohort study to develop frailty-based prognostic criteria in heart failure patients (FLAGSHIP): rationale and design
por: Yamada, Sumio, et al.
Publicado: (2018)

Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
por: Durães, André R., et al.
Publicado: (2018)

Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units
por: Naruse, Hiroyuki, et al.
Publicado: (2018)

Urinary Liver-Type Fatty-Acid-Binding Protein Predicts Long-Term Adverse Outcomes in Medical Cardiac Intensive Care Units
por: Naruse, Hiroyuki, et al.
Publicado: (2020)

Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study
por: Kawai, Mayumi, et al.
Publicado: (2019)

Asymmetry in histone rotation in forced unwrapping and force quench rewrapping in a nucleosome
por: Reddy, Govardhan, et al.
Publicado: (2021)

Combined Assessment of D-Dimer with the Get with the Guidelines—Heart Failure Risk Score and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Acute Decompensated Heart Failure with Preserved and Reduced Ejection Fraction
por: Naruse, Hiroyuki, et al.
Publicado: (2021)

A Resuscitated Adult With Left Main Coronary Artery Ostial Atresia and Graves’ Disease: 10-Year Follow-up
por: Kobayashi, Masakazu, et al.
Publicado: (2021)

An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination
por: Hoshino, Naoki, et al.
Publicado: (2022)

The Acute-Phase Ambulation Program Improves Clinical Outcome for Acute Heart Failure
por: Funato, Yusuke, et al.
Publicado: (2022)

Differences in Prognosis and Cardiac Function According to Required Percutaneous Mechanical Circulatory Support and Histological Findings in Patients With Fulminant Myocarditis: Insights From the CHANGE PUMP 2 Study
por: Kondo, Toru, et al.
Publicado: (2022)

Comparison Between Optical Frequency Domain Imaging and Intravascular Ultrasound for Percutaneous Coronary Intervention Guidance in Biolimus A9-Eluting Stent Implantation: A Randomized MISTIC-1 Non-Inferiority Trial
por: Muramatsu, Takashi, et al.
Publicado: (2020)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
por: Stolz, Leonie, et al.
Publicado: (2017)

Rivaroxaban versus warfarin for the management of left ventricle thrombus
por: Albabtain, Monirah A., et al.
Publicado: (2021)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

A combination of anatomical and functional evaluations improves the prediction of cardiac event in patients with coronary artery bypass
por: Kawai, Hideki, et al.
Publicado: (2013)

The ligand unwrapping/rewrapping pathway that exchanges metals in S-acetylated, hexacoordinate N(2)S(2)O(2) complexes
por: Denny, J. A., et al.
Publicado: (2015)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
por: Sherid, Muhammed, et al.
Publicado: (2016)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Prognostic score based on physical frailty in patients with heart failure: a multicenter prospective cohort study (FLAGSHIP)
por: Yamada, Sumio, et al.
Publicado: (2021)

Circulating miR-20b-5p and miR-330-3p are novel biomarkers for progression of atrial fibrillation: Intracardiac/extracardiac plasma sample analysis by small RNA sequencing
por: Harada, Masahide, et al.
Publicado: (2023)

Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis
por: Fusco, Julie A., et al.
Publicado: (2015)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Mechanical circulatory support devices for elective percutaneous coronary interventions: novel insights from the Japanese nationwide J-PCI registry
por: Muramatsu, Takashi, et al.
Publicado: (2022)

Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan
por: Kobayashi, Masakazu, et al.
Publicado: (2023)

Association between the ratio of anti-angiogenic isoform of VEGF-A to total VEGF-A and adverse clinical outcomes in patients after acute myocardial infarction
por: Harada, Kazuhiro, et al.
Publicado: (2018)

Differences in primary indication for guide-extension catheter usage among the three target vessels
por: Yoshida, Ruka, et al.
Publicado: (2020)

Combined prognostic value of malnutrition using GLIM criteria and renal insufficiency in elderly heart failure
por: Oguri, Mitsutoshi, et al.
Publicado: (2021)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency
por: Ameku, Koken, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rp15nbnfr5f787nq00qbi1nevc